Zacks Investment Research Downgrades Kaleido Biosciences (NASDAQ:KLDO) to Sell

Kaleido Biosciences (NASDAQ:KLDO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Kaleido Biosciences Inc. is a clinical-stage healthcare company. It focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies(TM), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido Biosciences Inc. is based in Lexington, Massachusetts. “

Separately, Chardan Capital assumed coverage on Kaleido Biosciences in a research note on Tuesday, April 23rd. They set a “buy” rating and a $17.50 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $17.70.

NASDAQ KLDO traded up $0.47 during trading hours on Wednesday, reaching $8.89. The company’s stock had a trading volume of 1,949 shares, compared to its average volume of 26,906. Kaleido Biosciences has a 1-year low of $6.23 and a 1-year high of $19.00. The firm has a 50-day moving average price of $9.21.

Kaleido Biosciences (NASDAQ:KLDO) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.09). As a group, equities analysts anticipate that Kaleido Biosciences will post -2.81 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new stake in Kaleido Biosciences during the 1st quarter worth approximately $1,390,000. Baillie Gifford & Co. purchased a new stake in Kaleido Biosciences during the 1st quarter worth approximately $6,380,000. Dean Capital Investments Management LLC purchased a new stake in Kaleido Biosciences during the 1st quarter worth approximately $611,000. FMR LLC purchased a new stake in Kaleido Biosciences during the 1st quarter worth approximately $25,143,000. Finally, Menta Capital LLC purchased a new stake in Kaleido Biosciences during the 2nd quarter worth approximately $164,000. Institutional investors own 77.83% of the company’s stock.

Kaleido Biosciences Company Profile

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

See Also: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Kaleido Biosciences (KLDO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kaleido Biosciences (NASDAQ:KLDO)

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.